Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.

NCT02767557 is registered in ClinicalTrials.gov with Herlev Hospital as lead sponsor.

NCT NCT02767557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02767557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multinational, Randomized, Phase II Study of the Combination of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab, an IL-6R Inhibitor, as First-line Treatment in Patients With Locally Advanced or Metastatic Pancreatic Cancer.
Lead sponsor
Herlev Hospital
Phase
Phase 2
Overall status
Completed
Start date
January 26, 2017
Completion date
January 1, 2023
Enrollment
147 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

unresectable pancreatic carcinoma